Dr. Joseph A. Weader, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 425 E 1st St, Ste 201, Bloomsburg, PA 17815 Phone: 570-416-1816 Fax: 570-416-1810 |
Dr. Amy V. Everett, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 425 E 1st St, Ste 201, Bloomsburg, PA 17815 Phone: 570-416-1816 Fax: 570-416-1810 |
Dr. Tapash K. Sengupta, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 425 E 1st St, Ste 201, Bloomsburg, PA 17815 Phone: 570-416-1816 Fax: 570-416-1810 |
Laura Elizabeth Spahr, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 425 East First St, Ste. 201, Bloomsburg, PA 17815 Phone: 570-416-1816 |
Dr. Amanda R. Manning, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 425 E 1st St, Ste 201, Bloomsburg, PA 17815 Phone: 570-416-1816 Fax: 570-416-1810 |
News Archive
Although antibodies induced by SARS-CoV-2 infection are largely protective, they do not completely protect against reinfection in young people, as evidenced through a longitudinal, prospective study of more than 3,000 young, healthy members of the US Marines Corps conducted by researchers at the Icahn School of Medicine at Mount Sinai and the Naval Medical Research Center, published April 15 in The Lancet Respiratory Medicine.
Scientists have uncovered an alternative source for some of the damage associated with multiple sclerosis, an incurable neuroinflammatory disorder. The research, published online by Cell Press on September 23rd in the journal Immunity, reveals a direct interaction between immune cells and neurons that plays a significant role in neuronal injury and may respond to therapeutic intervention.
FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.
The CHAMPION clinical trial was published online today in The Lancet. CHAMPION demonstrated a 30% reduction in the primary efficacy endpoint of heart failure hospitalization rates at 6 months, and a 39% reduction in heart failure hospitalization rates at 15 months for heart failure patients whose treatment was guided by pulmonary artery pressures obtained through a miniature, wireless sensor, compared to control patients receiving standard heart failure treatment.
New stem cell studies at the University of Maryland Dental School demonstrate that surgeons could one day routinely use strong, moldable, and injectable pastes to regenerate needed bone tissue to repair broken bones, fractures, genetic defects, even combat bone wounds.
› Verified 1 days ago